Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Madrigal Pharmaceuticals's enterprise value was $9.50B on Nov 11, 2026, against $12.78B a year earlier. Over the last 5 years it ranged from $671.67M to $12.78B, with a median of $4.79B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $9.50B | -23.7% |
| 2025 | Dec 31, 2025 | $12.45B | +113.0% |
| 2024 | Dec 31, 2024 | $5.84B | +40.4% |
| 2023 | Dec 29, 2023 | $4.16B | -14.4% |
| 2022 | Dec 30, 2022 | $4.86B | +330.2% |
| 2021 | Dec 31, 2021 | $1.13B | -18.4% |
| 2020 | Dec 31, 2020 | $1.38B | +45.3% |
| 2019 | Dec 31, 2019 | $952.14M | -23.6% |
| 2018 | Dec 31, 2018 | $1.25B | +9.9% |
| 2017 | Dec 29, 2017 | $1.13B | +591.5% |
| 2016 | Dec 30, 2016 | $164.00M | +318.4% |
| 2015 | Dec 31, 2015 | $39.20M | -76.4% |
| 2014 | Dec 31, 2014 | $166.41M | -38.2% |
| 2013 | Dec 31, 2013 | $269.26M | -36.6% |
| 2012 | Dec 31, 2012 | $424.88M | +153.6% |
| 2011 | Dec 30, 2011 | $167.51M | +33.1% |
| 2010 | Dec 31, 2010 | $125.80M | – |
See a number that looks wrong?